ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro in mPDAC"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro in mPDAC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Benjamin Weinberg

195 views

June 6, 2024

Chapters

EXPEL-PANC Trial & BXCL701 Mechanism

00:00

Phase II Study Design & Objectives

03:09

Preliminary Findings & Patient Responses

04:54

Comments 0

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

2024 ASCO® Annual Meeting Insights Hub: GI Videos

ASCO® 2024 Insights: "Botensilimab + Balstilimab in Microsatellite S…

2024 ASCO® Annual Meeting Insights Hub

A. Bullock

125 views

3 months ago

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

2024 ASCO® Annual Meeting Insights Hub

J. Knox

164 views

4 months ago

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

2024 ASCO® Annual Meeting Insights Hub

C. Eng

203 views

4 months ago

View All

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

2024 ASCO® Annual Meeting Insights Hub

E. Dotan

717 views

5 months ago

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

ASCO GI 2023 Conference Coverage

N. Uboha, A. Turk, K. Spencer, M. Cecchini

4.1K views

1 year ago

ASCO GI 2023 Key Studies

ASCO GI 2023 Conference Coverage

R. Kim, R. Mehta

3.1K views

1 year ago

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials Includ…

Insights from 2023 ASCO® Annual Meeting

Y. Janjigian, S. Cytryn, S. Maron

1.6K views

1 year ago

ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancrea…

2024 ESMO Annual Meeting Insights Hub

D. Melisi

222 views

1 month ago

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Sol…

UCSF School of Medicine

H. Kang

2.1K views

1 year ago

ASCO® 2024 Summary: "Advancing GI Cancer Treatment - The Clinical Ut…

2024 ASCO® Annual Meeting Insights Hub

S. Cohen

348 views

5 months ago

Targeting KRAS in Pancreatic Cancer

Harshabad Singh

314 views

5 months ago

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Total Health

A. Grothey

246 views

8 months ago

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ecancer

J. Knox

196 views

5 months ago

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

2024 ASCO® Annual Meeting Insights Hub

J. Knox

164 views

4 months ago

GI Oncology Year in Review: Precision Medicine Update in Metastatic …

Yale Cancer Center

J. Lacy

237 views

8 months ago

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

UCLA Health

Z. Wainberg

286 views

8 months ago

Clinical Takeaways in From Recent Key Trials in Pancreatic Cancer

Hani Babiker

129 views

2 months ago

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

Yale Cancer Center

J. Lacy

207 views

8 months ago

The TAPUR Study: Evaluating Targeted Therapies Based on Genetic Alte…

University of Miami Sylvester Comprehensive Cancer Center

R. Schilsky

138 views

2 months ago

Updates on Pancreatic Cancer - 2023 ASCO® Direct Philadelphia

Total Health

D. Lin

296 views

1 year ago

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

Insights from 2024 ESMO GI Annual Meeting

T. Seufferlein

125 views

4 months ago

FDA Approval of Liposomal Irinotecan/NALIRIFOX in 1L Metastatic Panc…

Shubham Pant

199 views

8 months ago

Pancreatic Cancer Updates From Yale Cancer Center

Yale Cancer Center

J. Lacy

270 views

11 months ago

AUTOPLAY

Login

Login

Join VuMedi

ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro in mPDAC"

EXPEL-PANC Trial & BXCL701 Mechanism

Phase II Study Design & Objectives

Preliminary Findings & Patient Responses

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

2024 ASCO® Annual Meeting Insights Hub: GI Videos

ASCO® 2024 Insights: "Botensilimab + Balstilimab in Microsatellite S…

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

Recommended

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

ASCO GI 2023 Key Studies

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials Includ…

ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancrea…

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Sol…

ASCO® 2024 Summary: "Advancing GI Cancer Treatment - The Clinical Ut…

Targeting KRAS in Pancreatic Cancer

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

GI Oncology Year in Review: Precision Medicine Update in Metastatic …

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

Clinical Takeaways in From Recent Key Trials in Pancreatic Cancer

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

The TAPUR Study: Evaluating Targeted Therapies Based on Genetic Alte…

Updates on Pancreatic Cancer - 2023 ASCO® Direct Philadelphia

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

FDA Approval of Liposomal Irinotecan/NALIRIFOX in 1L Metastatic Panc…

Pancreatic Cancer Updates From Yale Cancer Center